Octreotide Generics - Manufacturers & Suppliers
Sandostatin® , Sandostatin®
| Product/Composition:- | Octreotide |
|---|---|
| Strength:- | SQ: (0.5 mg/mL, 1 mg/mL, 3 mg/mL), Infusion: 0.25 mg/mL |
| Form:- | Subcutaneous Injection; IV Infusion |
| Reference Brands:- | Sandostatin® , Sandostatin® |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Octreotide (brand Sandostatin®) is used to treat carcinoid tumors, acromegaly, and GEP-NETs. Available in subcutaneous injections (0.5 mg/mL, 1 mg/mL, 3 mg/mL) and long-acting formulations (Sandostatin LAR®) (10 mg, 20 mg, 30 mg), it controls tumor-related symptoms like diarrhea and flushing by inhibiting hormone release. Available through GMP-compliant suppliers in the US and EU for oncology treatment.
Octreotide, marketed under the brand name Sandostatin®, is a somatostatin analogue used in oncology to manage carcinoid tumors, acromegaly, and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Available as subcutaneous injections (0.5 mg/mL, 1 mg/mL, 3 mg/mL) and long-acting injections (Sandostatin LAR®) (10 mg, 20 mg, 30 mg), it works by inhibiting hormone secretion, controlling tumor-induced symptoms like diarrhea and flushing. Sourced from GMP-certified suppliers, Octreotide is widely available for global distribution in US and EU markets. It provides reliable therapeutic options for oncologists and healthcare providers treating complex neuroendocrine tumors.